These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. Furiya Y; Ryo M; Kawahara M; Kiriyama T; Morikawa M; Ueno S Alzheimers Dement; 2013 Sep; 9(5):512-8. PubMed ID: 23142434 [TBL] [Abstract][Full Text] [Related]
6. Deciphering the Role of WNT Signaling in Metabolic Syndrome-Linked Alzheimer's Disease. Ali A; Ali A; Ahmad W; Ahmad N; Khan S; Nuruddin SM; Husain I Mol Neurobiol; 2020 Jan; 57(1):302-314. PubMed ID: 31325024 [TBL] [Abstract][Full Text] [Related]
7. The role of Wnt signaling in the development of Alzheimer's disease: a potential therapeutic target? Wan W; Xia S; Kalionis B; Liu L; Li Y Biomed Res Int; 2014; 2014():301575. PubMed ID: 24883305 [TBL] [Abstract][Full Text] [Related]
10. [Alzheimer's disease and fragile X syndrome: the Wnt/ß-catenin pathway as a common biological mechanism]. Rosales-Reynoso MA; Ochoa-Hernández AB; Juárez-Vázquez CI; Barros-Núñez P Rev Neurol; 2012 Nov; 55(9):543-8. PubMed ID: 23111993 [TBL] [Abstract][Full Text] [Related]
11. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Murray IV; Proza JF; Sohrabji F; Lawler JM Exp Biol Med (Maywood); 2011 Jul; 236(7):772-82. PubMed ID: 21680755 [TBL] [Abstract][Full Text] [Related]
12. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Frisardi V; Solfrizzi V; Seripa D; Capurso C; Santamato A; Sancarlo D; Vendemiale G; Pilotto A; Panza F Ageing Res Rev; 2010 Oct; 9(4):399-417. PubMed ID: 20444434 [TBL] [Abstract][Full Text] [Related]
13. Wnt signaling in Alzheimer's disease: up or down, that is the question. Boonen RA; van Tijn P; Zivkovic D Ageing Res Rev; 2009 Apr; 8(2):71-82. PubMed ID: 19101658 [TBL] [Abstract][Full Text] [Related]
14. Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. Ryu JC; Zimmer ER; Rosa-Neto P; Yoon SO Neurotherapeutics; 2019 Jul; 16(3):600-610. PubMed ID: 31270743 [TBL] [Abstract][Full Text] [Related]
15. The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism. Nixon DW Curr Alzheimer Res; 2017; 14(8):883-893. PubMed ID: 28215174 [TBL] [Abstract][Full Text] [Related]
16. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Chen Z; Zhong C Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509 [TBL] [Abstract][Full Text] [Related]
17. Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies. McGuire MJ; Ishii M Cell Mol Neurobiol; 2016 Mar; 36(2):203-17. PubMed ID: 26993509 [TBL] [Abstract][Full Text] [Related]
18. Octodon degus: a model for the cognitive impairment associated with Alzheimer's disease. Tarragon E; Lopez D; Estrada C; Ana GC; Schenker E; Pifferi F; Bordet R; Richardson JC; Herrero MT CNS Neurosci Ther; 2013 Sep; 19(9):643-8. PubMed ID: 23710760 [TBL] [Abstract][Full Text] [Related]
19. The long-lived Octodon degus as a rodent drug discovery model for Alzheimer's and other age-related diseases. Hurley MJ; Deacon RMJ; Beyer K; Ioannou E; Ibáñez A; Teeling JL; Cogram P Pharmacol Ther; 2018 Aug; 188():36-44. PubMed ID: 29514054 [TBL] [Abstract][Full Text] [Related]
20. Wnt signaling in the nervous system and in Alzheimer's disease. Inestrosa NC; Varela-Nallar L J Mol Cell Biol; 2014 Feb; 6(1):64-74. PubMed ID: 24549157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]